方法：2011-02/2013-02我院共有90例糖尿病性视网膜病变患者进行玻璃体切割手术治疗。以数字法随机分成观察组(45例)和对照组(45例)。对两组病患均进行玻璃体切割手术。观察组病患术前向玻璃体腔注射雷珠单抗，然后进行玻璃体切割术治疗糖尿病性视网膜病变。对照组病患只进行玻璃体切割手术。

结果：观察组疗效为优者占比71%(32/45)，优良率为89%(40/45)，均显著高于对照组的51%(23/45)，71%(32/45)，差异均有统计学意义(均P<0.05)。观察组出血量为9.64±2.27mL，眼内压为13.64±3.27mmHg，均显著少于对照组的10.21±3.14mL，16.00±3.14mmHg，差异均有统计学意义(均P<0.05)。

结论：玻璃体切割联合玻璃体腔注射雷珠单抗治疗糖尿病性视网膜病变，不仅可以减少术中出血，还能减少水肿，提升效果，安全性好，临床值得推荐。

METHODS: From February 2011 to February 2013, there were 90 cases in our hospital diabetic retinopathy patients withvitrectomy surgery. It was randomly divided into observation group(45 cases)and control group(45 cases). Two groups of patients were performed vitrectomy. Patients in observation group were injected intravitreal ranibizumab before surgery, then vitrectomy was underwent for diabetic retinopathy. Vitrectomy was only underwent in control group.

RESULTS: The patients in observation group with good effect accounting for 71%(32/45)and good rate was 89%(40/45), which were significantly higher than that in control group 51%(23/45), 71%(32/45). Differences were statistically significant(P<0.05). Amount of bleeding was 9.64±2.27mL, intraocular pressure was 13.64±3.27mmHg. It was significantly less than that in control group 10.21±3.14mL, 16.00±3.14mmHg. Differences were statistically significant(P<0.05).

CONCLUSION: The vitrectomy with intravitreal ranibizumab treatment of diabetic retinopathy can not only reduce blood loss, but also reduce edema and improve effectiveness and safety. It's worth recommending for clinical practice.